search
Back to results

Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence (CAR-Bern 2013)

Primary Purpose

Alcohol Craving, Psychological Stress, Physiological Stress

Status
Completed
Phase
Phase 3
Locations
Switzerland
Study Type
Interventional
Intervention
Cortisol 20mg
Placebo Mannitol
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Craving focused on measuring Cortisol, Alcohol Craving, Alcohol Dependence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18
  • Abstinent alcoholics in the 12-week in-patient program of the Clinic Südhang
  • Abstained from alcohol for at least 6 weeks
  • Voluntarily signed informed consent

Exclusion Criteria

  • Co-morbid psychiatric disturbances (such as major depression, bipolar disorder, schizophrenia)
  • Current medical conditions excluding participation (such as acute infectious disease)
  • Recent history of systemic or topic glucocorticoid therapy
  • Known hypersensitivity to the IMP under investigation (cortisol)
  • Pregnancy, breast-feeding
  • Inability to read and understand the participant's information
  • Positive alcohol test according to breathalyser

Sites / Locations

  • Klinik Südhang

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Cortisol first, Placebo second

Placebo first, Cortisol second

Arm Description

Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)

Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)

Outcomes

Primary Outcome Measures

Change from baseline in alcohol craving score
Measured by Alcohol Urge Questionnaire & Visual Analogue Scale

Secondary Outcome Measures

Change from baseline in State-Trait-Anger Expression Inventory STAXI
Change from baseline in heart rate variability
Saliva Cortisol Level

Full Information

First Posted
July 17, 2014
Last Updated
June 23, 2015
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT02196142
Brief Title
Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence
Acronym
CAR-Bern 2013
Official Title
Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
November 2014 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
June 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To investigate the effects of cortisol on alcohol craving and stress reactivity in alcohol addicted subjects. Randomized, double-blind, placebo-controlled, cross-over, single administration of study medication. Study hypothesis: Cortisol has an inhibiting effect on alcohol craving and stress reactivity in alcohol dependent subjects.
Detailed Description
Background Alcohol dependence is a chronically and relapsing disorder with major impact on the persons psychological, physiological and social functioning. There is extensive evidence from animal and human studies pointing out the important role of addiction memory in the development and maintenance of the disorder. Cognitive behavioural therapy (CBT) has proven its high effectiveness in the treatment for addictive disorders. A core element of CBT are exposure techniques that are comparable to extinction and habituation learning. The repeated exposure to alcohol related cues in the absence of alcohol ingestion will lead to extinction of conditioned responses, thus reducing the probability of relapse to alcohol taking behaviour. Studies have shown that glucocorticoids impair memory retrieval in healthy subjects. In fact, the investigators could show that cortisol has a fear reducing effect in patients with post-traumatic stress disorder and in phobic patients, resulting particularly in reduced symptoms of anxiety and in reduced stress reactivity. Interestingly enough, pharmacologically induced high levels of glucocorticoids lowered the subjective feeling of anxiety and stress in situations activating per se the HPA-axis. Further it has been shown that the combined therapy of glucocorticoid administration and exposition based psychotherapy leads to better therapy outcome in patients with specific phobias. Objective The goal of this study is to examine the acute effects of glucocorticoids administration on alcohol craving and stress reactivity of abstinent alcohol dependent patients. On the basis of clinical research in anxiety disorders, the investigators expect that a pharmacologically increased cortisol level may impair the retrieval of addiction memory, which is indicated by less craving during the alcohol exposition, while exposition therapy enhances consolidation of corrective experiences. Similar to the research in anxiety patients, the investigators aim to examine whether cortisol administration could help improve the effects of exposition therapy in patients with alcohol dependence. The purpose is to decrease therapy duration through cortisol administration in addition to already well proven therapies and make the therapy more efficient as well as a factor in reducing healthcare costs. Methods Patients undergo two identical experimental sessions between the 6th and 8th week (one week in between) of their 12-week inpatient treatment program for alcohol dependence. The experiment takes place in the experimental rooms of the clinic Südhang between 1 and 6 pm. One hour before the confrontation with alcohol associated stimuli patients receive either 20mg of hydrocortisone or placebo (oral administration). The experiment consists of a computer based picture task (alcoholic and neutral pictures) and an in-vivo exposure task. Psychological (craving, stress, arousal) and physiological (heart rate, saliva cortisol) parameters are repeatedly measured over the course of the experiment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Craving, Psychological Stress, Physiological Stress
Keywords
Cortisol, Alcohol Craving, Alcohol Dependence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
48 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cortisol first, Placebo second
Arm Type
Active Comparator
Arm Description
Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
Arm Title
Placebo first, Cortisol second
Arm Type
Active Comparator
Arm Description
Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
Intervention Type
Drug
Intervention Name(s)
Cortisol 20mg
Intervention Description
Drug: Cortisol 20mg
Intervention Type
Drug
Intervention Name(s)
Placebo Mannitol
Intervention Description
Drug: Placebo Mannitol
Primary Outcome Measure Information:
Title
Change from baseline in alcohol craving score
Description
Measured by Alcohol Urge Questionnaire & Visual Analogue Scale
Time Frame
During and after presentation of drug stimuli, expected to be after 10 minutes
Secondary Outcome Measure Information:
Title
Change from baseline in State-Trait-Anger Expression Inventory STAXI
Time Frame
After presentation of drug stimuli, expected to be after 20 minutes
Title
Change from baseline in heart rate variability
Time Frame
During and after presentation of drug stimuli, expected to be after 10 minutes
Title
Saliva Cortisol Level
Time Frame
After presentation of drug stimuli, expected to be after 90 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 Abstinent alcoholics in the 12-week in-patient program of the Clinic Südhang Abstained from alcohol for at least 6 weeks Voluntarily signed informed consent Exclusion Criteria Co-morbid psychiatric disturbances (such as major depression, bipolar disorder, schizophrenia) Current medical conditions excluding participation (such as acute infectious disease) Recent history of systemic or topic glucocorticoid therapy Known hypersensitivity to the IMP under investigation (cortisol) Pregnancy, breast-feeding Inability to read and understand the participant's information Positive alcohol test according to breathalyser
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leila Soravia, Dr. phil.
Organizational Affiliation
University Hospital of Psychiatry Bern
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Peter Allemann, Dr. med.
Organizational Affiliation
Clinic Südhang
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dominique de Quervain, Prof. Dr.
Organizational Affiliation
University Hospital, Basel, Switzerland
Official's Role
Study Chair
Facility Information:
Facility Name
Klinik Südhang
City
Kirchlindach
State/Province
Bern
ZIP/Postal Code
CH-3038
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence

We'll reach out to this number within 24 hrs